Coherus BioSciences (CHRS) Reports Q3 EPS of $1.67
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Coherus BioSciences Reports Third Quarter 2016 Operating and Financial Results
November 9, 2016 4:01 PM ESTREDWOOD CITY, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reported financial results and reviewed corporate events for the third quarter ended September 30, 2016.
Corporate Highlights for the Third Quarter 2016 Include:Oncology therapeutic franchise:
CHS-1701 (pegfilgrastim (Neulasta®) biosimilar candidate) U.S. Food and Drug Administration filing of the CHS-1701 biologics license application (BLA).Positive topline results from follow-on pharmacokinetic and pharmacodynamic (PK/PD) clinical study CHS-1701-05. All co-primary endpoints for PK, Cmax and Area Under the Curve (AUC), and PD, absolute... More